InvestLog
CVKD Cadrenal Therapeutics, Inc. Common Stock logo

CVKD Cadrenal Therapeutics, Inc. Common Stock

Healthcare
$5.19+0.39%ClosedMarket Cap: $14.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

6.95

P/S

0.00

EV/EBITDA

-1.05

DCF Value

$1.72

FCF Yield

-73.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-411.0%

ROA

-415.4%

ROIC

-670.4%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-2.5M$—
Q4 null$0.00$-3.0M$—
FY null$0.00$-13.2M$—
Q3 null$0.00$-2.7M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$32.00

Target (Median)

$32.00

Target Range

$32.00 - $32.00

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-04-07

Trading Activity

Insider Trades

View All
Szot Matthew Kofficer: Chief Financial Officer
SellWed Dec 31
Golden Lee Scottdirector
SellWed Dec 03
Golden Lee Scottdirector
SellWed Dec 03
Szot Matthew Kofficer: Chief Financial Officer
SellTue Oct 28
Pham Quang Xdirector, 10 percent owner, officer: CEO and Chairman
SellTue Oct 28

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

1.83

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Peers

CLGN logoCLGNIBIO logoIBIOITRM logoITRMKLTO logoKLTONRSN logoNRSNNRXS logoNRXSRLYB logoRLYBSONN logoSONNTAOX logoTAOXXCUR logoXCUR